Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.

Autor: Kudriavtsev AV; Betuvax LLC, 121096 Moscow, Russia., Vakhrusheva AV; Betuvax LLC, 121096 Moscow, Russia., Kryuchkov NA; Clinical Excellence Group LLC, 127051 Moscow, Russia., Frolova ME; PJSC Human Stem Cells Institute, 129110 Moscow, Russia., Blagodatskikh KA; Center of Genetics and Reproductive Medicine 'Genetico', 119333 Moscow, Russia., Ivanishin TV; Betuvax LLC, 121096 Moscow, Russia.; PJSC Human Stem Cells Institute, 129110 Moscow, Russia., Djonovic M; PJSC Human Stem Cells Institute, 129110 Moscow, Russia., Romanovskaya-Romanko EA; Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 Saint Petersburg, Russia., Kovalenko AN; Clinical Excellence Group LLC, 127051 Moscow, Russia., Lioznov DA; Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 Saint Petersburg, Russia., Zubkova TG; Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 Saint Petersburg, Russia., Teplykh SV; Professor Clinic LLC, 614070 Perm, Russia., Oseshnyuk RA; Ecosafety Center LLC, 195000 Saint Petersburg, Russia., Stukova MA; Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 Saint Petersburg, Russia., Isaev AA; PJSC Human Stem Cells Institute, 129110 Moscow, Russia., Krasilnikov IV; Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197376 Saint Petersburg, Russia.; Biotechnology Developments LLC, 119285 Moscow, Russia.

Publikováno v: Vaccines [Vaccines (Basel)] 2023 Feb 01; Vol. 11 (2). Date of Electronic Publication: 2023 Feb 01.